AbbVie Inc. Net Cash Provided by (Used in) Continuing Operations
AbbVie Inc. (ABBV) reported Net Cash Provided by (Used in) Continuing Operations of -$442.00 million for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-05-08.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:NetCashProvidedByUsedInContinuingOperations · last filed 2015-05-08
- AbbVie Inc. net cash provided by (used in) continuing operations for the quarter ending 2015-03-31 was -$442.00M.
- AbbVie Inc. net cash provided by (used in) continuing operations for the quarter ending 2014-12-31 was $629.00M, a 1.45% increase year-over-year.
- AbbVie Inc. net cash provided by (used in) continuing operations for the quarter ending 2014-09-30 was -$1.37B, a 689.22% decline year-over-year.
- AbbVie Inc. net cash provided by (used in) continuing operations for the quarter ending 2014-06-30 was $946.00M, a 46.37% decline year-over-year.
- AbbVie Inc. net cash provided by (used in) continuing operations for fiscal 2014 was -$1.25B, a 133.76% decline from fiscal 2013.
- AbbVie Inc. net cash provided by (used in) continuing operations for fiscal 2013 was $3.69B, a 37.11% decline from fiscal 2012.
- AbbVie Inc. net cash provided by (used in) continuing operations for fiscal 2012 was $5.87B, a 34452.94% increase from fiscal 2011.
- AbbVie Inc. net cash provided by (used in) continuing operations for fiscal 2011 was $17.00M.
| Period end | Net Cash Provided by (Used in) Continuing Operations 3 month | Net Cash Provided by (Used in) Continuing Operations 6 month | Net Cash Provided by (Used in) Continuing Operations 9 month | Net Cash Provided by (Used in) Continuing Operations 12 month |
|---|---|---|---|---|
| 2015-03-31 | -$442.00M 10-Q · filed 2015-05-08 | $187.00M derived: sum of 2 quarters · filed 2015-05-08 | -$1.18B derived: sum of 3 quarters · filed 2015-05-08 | -$234.00M derived: sum of 4 quarters · filed 2015-05-08 |
| 2014-12-31 | $629.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | -$738.00M derived: sum of 2 quarters · filed 2015-02-20 | $208.00M derived: sum of 3 quarters · filed 2015-02-20 | -$1.25B 10-K · filed 2015-02-20 |
| 2014-09-30 | -$1.37B derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$421.00M derived: sum of 2 quarters · filed 2014-11-07 | -$1.88B 10-Q · filed 2014-11-07 | -$1.26B derived: sum of 4 quarters · filed 2015-05-08 |
| 2014-06-30 | $946.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$509.00M 10-Q · filed 2014-08-07 | $111.00M derived: sum of 3 quarters · filed 2015-05-08 | $343.00M derived: sum of 4 quarters · filed 2015-05-08 |
| 2014-03-31 | -$1.46B 10-Q · filed 2015-05-08 | -$835.00M derived: sum of 2 quarters · filed 2015-05-08 | -$603.00M derived: sum of 3 quarters · filed 2015-05-08 | $1.16B derived: sum of 4 quarters · filed 2015-05-08 |
| 2013-12-31 | $620.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | $852.00M derived: sum of 2 quarters · filed 2015-02-20 | $2.62B derived: sum of 3 quarters · filed 2015-02-20 | $3.69B 10-K · filed 2015-02-20 |
| 2013-09-30 | $232.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $2.00B derived: sum of 2 quarters · filed 2014-11-07 | $3.07B 10-Q · filed 2014-11-07 | $6.21B derived: sum of 4 quarters · filed 2015-02-20 |
| 2013-06-30 | $1.76B derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $2.84B 10-Q · filed 2014-08-07 | $5.98B derived: sum of 3 quarters · filed 2015-02-20 | $8.67B derived: sum of 4 quarters · filed 2015-02-20 |
| 2013-03-31 | $1.08B 10-Q · filed 2014-05-09 | $4.22B derived: sum of 2 quarters · filed 2015-02-20 | $6.91B derived: sum of 3 quarters · filed 2015-02-20 | $6.94B derived: sum of 4 quarters · filed 2015-02-20 |
| 2012-12-31 | $3.14B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | $5.83B derived: sum of 2 quarters · filed 2015-02-20 | $5.86B derived: sum of 3 quarters · filed 2015-02-20 | $5.87B 10-K · filed 2015-02-20 |
| 2012-09-30 | $2.69B derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $2.72B derived: sum of 2 quarters · filed 2013-11-12 | $2.73B 10-Q · filed 2013-11-12 | |
| 2012-06-30 | $33.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $47.00M 10-Q · filed 2013-08-09 | ||
| 2012-03-31 | $14.00M 10-Q · filed 2013-05-08 | |||
| 2011-12-31 | $17.00M 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |